Esophageal varices: nursing assessment, management, and NCLEX review

Esophageal varices are dilated submucosal veins in the distal esophagus that develop when portal hypertension forces blood through portosystemic collateral pathways. Approximately 30% to 40% of patients with compensated cirrhosis have varices at diagnosis, and without prophylaxis, 25% to 30% of those with medium or large varices will experience a hemorrhagic episode within two years. Six-week mortality after an acute variceal bleed is 15% to 20%, varying with Child-Pugh class and MELD score – lower than the 30%-plus figures quoted in older textbooks, because vasoactive drugs, prophylactic antibiotics, and early band ligation have all improved outcomes. This makes variceal hemorrhage one of the most lethal GI emergencies a nurse will manage. Recognizing the early hemodynamic signs, understanding pharmacologic and endoscopic interventions, and knowing what to prioritize during an active bleed are essential competencies tested on the NCLEX and used daily in ICU, med-surg, and hepatology settings.

Pathophysiology: portal hypertension and variceal formation

Esophageal varices develop through a predictable hemodynamic sequence that begins with increased resistance to portal blood flow and ends with rupture of thin-walled collateral vessels. Understanding this pathway connects directly to the rationale behind every treatment intervention.

Increased intrahepatic resistance. In cirrhosis, fibrotic remodeling and regenerative nodules compress the hepatic sinusoids and increase resistance to portal blood flow. This structural component accounts for approximately 70% of the increased portal pressure. The remaining 30% comes from a functional component – increased intrahepatic vascular tone driven by endothelin-1 overproduction and reduced nitric oxide availability within the liver.

Splanchnic vasodilation. As portal pressure rises, the splanchnic (mesenteric) vascular bed responds by overproducing vasodilators – primarily nitric oxide, prostaglandins, and glucagon. This progressive splanchnic arterial vasodilation increases blood flow into the portal system, further raising portal pressure. The result is a self-amplifying cycle: higher portal pressure causes more vasodilation, which drives more blood into an already congested portal system.

Portosystemic collateral formation. When the hepatic venous pressure gradient (HVPG) exceeds 10 mmHg – defined as clinically significant portal hypertension (CSPH) – blood seeks alternative pathways back to systemic circulation. The most clinically important collaterals form at the gastroesophageal junction, where the left gastric (coronary) vein connects with the esophageal venous plexus draining into the azygos system. These dilated submucosal veins in the distal esophagus are esophageal varices.

Variceal wall tension and rupture. The risk of variceal rupture depends on wall tension, governed by LaPlace’s law: wall tension = (transmural pressure x variceal radius) / wall thickness. As portal pressure increases (raising transmural pressure), varices enlarge (increasing radius), and the vessel wall thins. When wall tension exceeds the elastic limit of the vessel, rupture occurs. This is why bleeding risk correlates with variceal size and HVPG – specifically, varices rarely bleed when HVPG is below 12 mmHg.

Grading and classification

Endoscopy is the gold standard for identifying and grading esophageal varices. Endoscopists use either a three-size scale (small, medium, large), which parallels the Japanese F1–F3 form grading, or the two-size scale used by Baveno VII, which calls varices small below 5 mm and large at 5 mm or more. AASLD guidance manages medium varices the same way as large ones. The North Italian Endoscopic Club (NIEC) index is a different tool: it combines variceal size, red wale marks, and Child-Pugh class to predict the risk of a first bleed.

Small varices (F1). Straight veins that minimally protrude into the esophageal lumen. These flatten with insufflation during endoscopy. Annual bleeding risk is approximately 5% per year.

Medium varices (F2). Tortuous, slightly enlarged veins occupying less than one-third of the esophageal lumen. They do not flatten with insufflation. Presence of red wale signs elevates bleeding risk significantly.

Large varices (F3). Coiling veins that occupy more than one-third of the esophageal lumen. Annual first-bleed risk is approximately 15% per year. These require primary prophylaxis regardless of other factors.

Red wale signs

Red wale markings are the most important endoscopic risk markers for impending hemorrhage. These appear as longitudinal red streaks on the variceal surface representing microtelangiectasias in the variceal wall. Additional high-risk endoscopic features include cherry red spots (small, discrete red dots), hematocystic spots (blood-filled blisters – the highest-risk finding), and diffuse mucosal redness over the varix. The combination of large variceal size plus red wale signs in a Child-Pugh C patient represents the highest bleeding risk category.

Screening recommendations

Per Baveno VII (2022), patients with compensated advanced chronic liver disease (cACLD) who have liver stiffness below 20 kPa and a platelet count above 150,000/microL have a very low risk of high-risk varices and can avoid screening endoscopy. Baveno VIII (2026) states that recommendations it did not specifically revise remain valid, and it revised several other non-invasive cut-offs, so check local protocols against the current text. These patients are monitored with yearly transient elastography and platelet counts instead. Patients already taking a non-selective beta-blocker (NSBB) for clinically significant portal hypertension do not need screening endoscopy, because the result would not change treatment. Other patients undergo upper endoscopy, and surveillance intervals depend on variceal size and on whether the cause of the liver disease has been removed or controlled.

Nursing assessment

Assessment priorities for a patient with known or suspected esophageal varices depend on whether the patient is stable (surveillance phase) or actively bleeding.

Stable patient assessment

For patients with known varices who are not bleeding, nursing assessment focuses on identifying risk factors for decompensation and monitoring for early signs of hemorrhage:

• History: Etiology of liver disease (alcohol, hepatitis B or C, NAFLD), prior variceal bleeding episodes, current medications (beta-blocker adherence, NSAIDs – which increase bleeding risk), alcohol use status
• Hepatic function indicators: Ascites presence and severity, hepatic encephalopathy grade, jaundice, Spider angiomata – these contribute to Child-Pugh scoring (A, B, or C) which directly predicts bleeding risk and mortality
• Baseline labs: Platelets (thrombocytopenia below 150,000 suggests portal hypertension), INR (coagulopathy), albumin (synthetic function), creatinine (renal function – relevant for hepatorenal syndrome risk), hemoglobin baseline
• MELD score awareness: The original Model for End-Stage Liver Disease uses bilirubin, INR, and creatinine to predict 90-day mortality; US organ allocation now uses MELD 3.0, which adds sodium, albumin, and sex. A MELD score above 18 significantly increases post-bleed mortality

Active bleeding assessment

When a patient with esophageal varices presents with hematemesis (bright red or coffee-ground emesis) or melena, the assessment shifts to rapid hemodynamic evaluation:

• Airway first. Massive upper GI hemorrhage carries a high aspiration risk. Assess level of consciousness, gag reflex, and airway patency. Patients with altered mental status (from hepatic encephalopathy or hemorrhagic shock) or massive hematemesis often require emergent intubation before any other intervention.
• Hemodynamic status. Heart rate (tachycardia above 100 bpm is often the earliest sign), blood pressure (systolic below 90 mmHg indicates class III or IV shock), mean arterial pressure (target above 65 mmHg), orthostatic vital signs if the patient can sit safely, capillary refill, and skin color/temperature.
• Hemorrhage volume estimation. Serial hemoglobin and hematocrit (note: initial values may be falsely normal in acute hemorrhage before equilibration), urine output (goal above 0.5 mL/kg/hr), and lactate level.
• Two large-bore IVs (16-gauge or larger) immediately. Send type and crossmatch, CBC, CMP, coagulation studies, and lactate with the initial draw.

Primary prophylaxis

Primary prophylaxis aims to prevent the first variceal bleed in patients with medium or large varices. The Baveno consensus (Baveno VII, 2022, and Baveno VIII, 2026) and the 2024 AASLD practice guidance both recommend NSBBs first, with band ligation for patients who cannot take them.

Non-selective beta-blockers

NSBBs reduce portal pressure by decreasing cardiac output (beta-1 blockade) and causing splanchnic vasoconstriction (beta-2 blockade). They reduce first-bleed risk from approximately 25% to 15% over two years.

• Carvedilol (6.25 mg daily, may titrate to 12.5 mg daily) is the preferred NSBB per Baveno VII due to its additional alpha-1 blocking activity, which reduces intrahepatic vascular resistance. Carvedilol produces a greater reduction in HVPG than propranolol or nadolol. Baveno VII and Baveno VIII recommend NSBBs, preferably carvedilol, for compensated patients with clinically significant portal hypertension to prevent decompensation, whether or not varices are present.
• Propranolol (20 mg twice daily, titrated to a resting heart rate of 55 to 60 bpm, maximum 320 mg/day) remains an alternative.
• Nadolol (40 mg daily, titrated similarly to heart rate target) is used when propranolol is not tolerated.

Nursing considerations for NSBB therapy: Monitor heart rate (hold if below 55 bpm), blood pressure (hold if systolic below 90 mmHg or MAP below 65 mmHg), and for signs of bronchospasm in patients with reactive airway disease. In patients with ascites, Baveno VII advises reducing the dose or stopping the NSBB if blood pressure stays low (systolic below 90 mmHg or MAP below 65 mmHg) or HRS-AKI develops, then restarting or re-titrating once blood pressure and kidney function recover. This is the so-called “NSBB window”: beta-blockers help portal hypertension, but in advanced disease they can harm systemic hemodynamics and renal perfusion.

Endoscopic variceal ligation

EVL (banding) is recommended for patients with medium or large varices who have contraindications or intolerance to NSBBs. Bands are placed on the varices to necrose and obliterate them. Sessions are repeated every 2 to 4 weeks until variceal eradication, then surveillance endoscopy follows (AASLD 2024 suggests about 6 months after eradication, then yearly). Some endoscopists prescribe a short proton pump inhibitor course after banding to limit post-banding ulcers, but AASLD 2024 advises stopping PPIs that have no specific indication, because long-term use in cirrhosis is linked to infection and hepatic encephalopathy.

Acute variceal hemorrhage management

Acute variceal bleeding is a medical emergency requiring simultaneous resuscitation, pharmacotherapy, and endoscopic intervention. The sequence below reflects current AASLD guidance and the Baveno consensus (Baveno VII recommendations remain valid where Baveno VIII, 2026, did not revise them).

Step 1: Airway and hemodynamic stabilization

Airway protection is the first priority. Patients with massive hematemesis, altered mental status, or hemodynamic instability should be intubated before endoscopy. Establish two large-bore peripheral IVs and begin crystalloid resuscitation. Blood transfusion follows a restrictive strategy: transfuse when hemoglobin falls below 7 g/dL, aiming for 7 to 8 g/dL (Baveno VII). The landmark trial used a 7 g/dL threshold with a 7 to 9 g/dL target. Over-transfusion raises portal pressure and increases rebleeding risk. Avoid aggressive volume resuscitation for the same reason.

Step 2: Vasoactive drug therapy

Vasoactive agents should be started as soon as variceal hemorrhage is suspected – before endoscopy, before lab confirmation, and ideally in the emergency department.

• Octreotide (most commonly used in the United States): 50 mcg IV bolus followed by a continuous infusion of 50 mcg/hr for 2 to 5 days. Octreotide inhibits splanchnic vasodilation and reduces portal blood flow.
• Terlipressin (a vasopressin analog): 2 mg IV every 4 hours for the first 48 hours, then reduced to 1 mg IV every 4 hours. Terlipressin directly constricts splanchnic arterioles, reducing portal inflow, and is the only vasoactive agent shown to reduce mortality against placebo in variceal bleeding. US availability caveat: terlipressin is licensed for variceal hemorrhage in Europe and much of the rest of the world, but the US product (Terlivaz, approved September 2022) is labeled only for hepatorenal syndrome with rapid reduction in kidney function. US use in variceal bleeding is therefore off-label. Octreotide is off-label for this indication too (Sandostatin is labeled for acromegaly, carcinoid tumors, and VIPomas), but it is the agent US practice has long relied on, and it carries no boxed warning. Monitor for ischemic complications (mesenteric, cardiac, peripheral), respiratory failure, and hyponatremia.
• Somatostatin (used in some European centers): 250 mcg IV bolus followed by 250 mcg/hr infusion.

Step 3: Prophylactic antibiotics

Antibiotics are started immediately – ideally before endoscopy – because bacterial infections occur in up to 50% of cirrhotic patients with GI bleeding and are an independent predictor of rebleeding and mortality. Prophylaxis reduces infections, rebleeding, and mortality. The 2021 AASLD guidance sets IV ceftriaxone 1 g every 24 hours as the antibiotic of choice for a maximum of 7 days, continued until the bleeding has resolved and vasoactive drugs are stopped. Baveno VIII (2026) keeps antibiotics at presentation and allows the duration to be individualized by infection risk and severity of cirrhosis.

• Ceftriaxone 1 g IV every 24 hours is the preferred agent for patients with advanced cirrhosis (Child-Pugh B or C) or in settings with high quinolone resistance.
• Norfloxacin 400 mg orally twice daily is the agent used in the original trials and still appears in international guidance, but it has not been marketed in the United States since 2014. US practice substitutes ciprofloxacin 500 mg orally twice daily or 400 mg IV twice daily, and ceftriaxone is preferred outright where quinolone resistance is common.

Step 4: Emergent endoscopy with EVL

Upper endoscopy should be performed within 12 hours of presentation. Erythromycin (250 mg IV, given 30 to 120 minutes before endoscopy) improves gastric visualization by promoting gastric emptying. EVL is the endoscopic treatment of choice – it has lower rebleeding rates, fewer complications, and faster variceal eradication than sclerotherapy. Successful hemostasis is achieved in approximately 90% of cases.

NG tube precaution: Nasogastric tube insertion is avoided in patients with known unligated esophageal varices due to the risk of mechanical trauma and hemorrhage provocation. If gastric decompression is required before endoscopy, the decision should be made by the endoscopy or critical care team with full awareness of the variceal status.

Step 5: Rescue therapies for refractory bleeding

Approximately 10% to 20% of variceal hemorrhages are refractory to standard pharmacologic and endoscopic therapy. Rescue options include:

• Balloon tamponade (Sengstaken-Blakemore tube or Minnesota tube). A temporary bridge measure that achieves initial hemostasis in about 90% of cases by direct compression of varices, although bleeding often recurs (34% rebled during admission in one 80-patient cohort). It is a temporizing measure only – placement is limited to a maximum of 24 hours because of serious complications, including esophageal necrosis, perforation, and aspiration. The patient must be intubated before insertion. Gastric balloon is inflated first (250 to 300 mL air), confirmed by X-ray, then traction is applied. The esophageal balloon is inflated only if gastric balloon tamponade fails. Continuous monitoring of balloon pressures and respiratory status is mandatory.
• Self-expanding metal stent (SEMS). Baveno VII lists a covered esophageal stent as an alternative bridge to TIPS: it is as effective as balloon tamponade and safer, and it can stay in place longer.
• Transjugular intrahepatic portosystemic shunt (TIPS). TIPS creates a low-resistance channel between the portal vein and the hepatic vein, decompressing the portal system. Preemptive (early) TIPS – placed within 72 hours, ideally within 24 hours – is recommended for high-risk patients (Child-Pugh C with a score below 14, Child-Pugh B above 7 with active bleeding at initial endoscopy, or HVPG above 20 mmHg at the time of bleeding, per Baveno VII; published summaries of Baveno VIII report that patients who miss the 72-hour window may still benefit from TIPS within about 1–2 weeks) and has been shown to improve survival and reduce treatment failure. Rescue TIPS is used when EVL and pharmacotherapy fail. The primary complication of TIPS is hepatic encephalopathy (occurring in 25% to 45% of patients) and shunt occlusion or stenosis, requiring surveillance Doppler studies.

Secondary prophylaxis

After surviving a first variceal bleed, patients face about a 60% risk of rebleeding within 1–2 years if no secondary prophylaxis is instituted. The standard of care per the Baveno consensus and AASLD is combination therapy.

EVL plus NSBBs together. Combination therapy is superior to either intervention alone for preventing rebleeding. EVL sessions are repeated every 2 to 4 weeks until variceal eradication, with the first session typically performed 1 to 2 weeks after the acute bleed resolves. NSBBs (propranolol, nadolol, or carvedilol) are initiated as soon as the patient is hemodynamically stable, typically before hospital discharge.

Monitoring. After variceal eradication, surveillance endoscopy is repeated at intervals set by the hepatology team (AASLD 2024 suggests about 6 months after eradication, then yearly), because varices can reform. NSBB dosing is titrated to a resting heart rate of 55 to 60 bpm with systolic BP maintained above 90 mmHg. Patients should be evaluated for liver transplant candidacy, which is the definitive treatment for the underlying portal hypertension.

TIPS for secondary prophylaxis. TIPS is reserved for patients who rebleed despite combination EVL plus NSBB therapy. After TIPS, a portosystemic pressure gradient below 12 mmHg is associated with near-complete protection from rebleeding. (The separate “HVPG to 12 mmHg or below, or a fall of at least 20% from baseline” target describes a good hemodynamic response to NSBB therapy.)

NCLEX priorities and clinical decision scenarios

The following decision points reflect the high-yield testing concepts for esophageal varices nursing care.

1. Airway before bleeding control. A patient with massive hematemesis and altered mental status requires intubation before endoscopy or any other intervention. Airway protection is always the first priority, because aspiration of blood is a major and preventable cause of early harm in massive variceal hemorrhage.

2. Restrictive transfusion in variceal bleeding. The transfusion threshold is a hemoglobin of 7 g/dL, with a target of 7 to 8 g/dL. Transfusing to higher levels raises portal pressure and increases rebleeding risk. If an NCLEX question asks about transfusion threshold in a patient with GI bleeding from varices, the answer is lower than a typical surgical patient.

3. Start vasoactive drugs before endoscopy. Octreotide (or terlipressin) is started on clinical suspicion of variceal hemorrhage – do not wait for endoscopic confirmation. If a question presents a patient with known cirrhosis and hematemesis, the immediate nursing action after airway and IV access is to initiate the vasoactive infusion.

4. Beta-blocker parameters. Hold propranolol, nadolol, or carvedilol if heart rate is below 55 bpm or systolic BP is below 90 mmHg. Report these findings to the provider. NSBBs should never be initiated during an active bleed – they are for prophylaxis only.

5. Sengstaken-Blakemore tube complications. The two most tested complications are esophageal rupture (from over-inflation or prolonged placement beyond 24 hours) and airway obstruction (if the gastric balloon deflates and the tube migrates upward). The patient must be intubated. Scissors must be kept at the bedside to cut and deflate the balloon immediately if airway obstruction occurs.

6. Antibiotics are mandatory in variceal bleeding. Prophylactic antibiotics are given to every cirrhotic patient with GI bleeding – this is a standard of care, not an optional add-on. They reduce mortality, rebleeding, and bacterial peritonitis rates. If a question asks which orders to clarify on a variceal bleed patient, the absence of antibiotic orders should be questioned.

7. TIPS and encephalopathy risk. A patient who underwent TIPS placement should be monitored for new or worsening hepatic encephalopathy. Post-TIPS encephalopathy develops in 25% to 45% of patients. The nursing assessment includes orientation checks, asterixis evaluation, and lactulose/rifaximin administration.

8. Avoid NSAIDs in cirrhotic patients. Non-steroidal anti-inflammatory drugs impair platelet function and increase the risk of variceal and non-variceal bleeding in patients with cirrhosis. Acetaminophen (limited to 2 g/day in cirrhosis) is the preferred analgesic.

NANDA-I nursing care plans for esophageal varices

The five diagnoses below address the primary clinical threats in esophageal varices: hemorrhage, hemodynamic collapse, fluid deficit, psychological burden, and knowledge gaps that drive non-adherence and readmission. Each diagnosis includes esophageal-varices-specific rationale rather than generic GI guidance.

Nursing diagnosis 1: risk for bleeding

NANDA-I label: Risk for Bleeding

Related to: Elevated portal venous pressure (HVPG ≥12 mmHg), dilated thin-walled esophageal collateral vessels subject to LaPlace tension, thrombocytopenia from splenic sequestration, coagulopathy from impaired hepatic synthesis of clotting factors (II, V, VII, IX, X), and platelet dysfunction from uremia and alcohol exposure.

Risk factors (no AEB required for risk diagnoses): Child-Pugh B or C disease, MELD score above 18, large F3 varices on endoscopy, presence of red wale signs, prior variceal bleed episode, active alcohol use, NSAID or anticoagulant use, thrombocytopenia below 50,000/mcL.

Nursing diagnosis 2: decreased cardiac output

NANDA-I label: Decreased Cardiac Output

Related to: Hemorrhagic hypovolemia secondary to acute variceal rupture, reduced preload from massive blood and fluid loss, compensatory tachycardia with decreased stroke volume, and vasodilatation from endogenous mediators (nitric oxide, prostaglandins) released in decompensated portal hypertension.

As evidenced by: Hypotension (systolic BP below 90 mmHg or MAP below 65 mmHg), tachycardia above 100 bpm, decreased urine output below 0.5 mL/kg/hr, cold and clammy skin, altered mental status, elevated lactate above 2 mmol/L, hemoglobin below threshold.

Nursing diagnosis 3: deficient fluid volume

NANDA-I label: Deficient Fluid Volume

Related to: Active hemorrhage from ruptured esophageal varices causing acute intravascular volume depletion, third-spacing of fluid into the peritoneal cavity (ascites) and interstitial spaces driven by hypoalbuminemia and elevated portal pressure, and renal sodium and water retention paradoxically reducing effective circulating volume.

As evidenced by: Decreased blood pressure, tachycardia, dry mucous membranes, decreased skin turgor, decreased urine output, concentrated urine (specific gravity above 1.025), elevated BUN:creatinine ratio above 20:1, weight loss with concurrent abdominal distension from ascites.

Nursing diagnosis 4: anxiety

NANDA-I label: Anxiety

Related to: Fear of recurrent life-threatening hemorrhage, uncertainty regarding disease prognosis and liver transplant candidacy, powerlessness over disease progression, ICU environment, and awareness that esophageal varices represent advanced liver disease with limited curative options.

As evidenced by: Verbalization of fear, restlessness, insomnia, increased heart rate and respiratory rate in the absence of bleeding, requests for repeated reassurance, refusal of procedures (EVL, TIPS), and expressions of hopelessness regarding prognosis.

Nursing diagnosis 5: deficient knowledge

NANDA-I label: Deficient Knowledge

Related to: Lack of prior exposure to esophageal varices management, complexity of multi-drug prophylaxis regimens, limited health literacy secondary to hepatic encephalopathy in some cirrhotic patients, and inadequate prior education regarding variceal surveillance and lifestyle modification.

As evidenced by: Verbalization of unawareness of variceal diagnosis, inaccurate statements about medication purpose, report of missed NSBB doses, non-adherence to EVL follow-up scheduling, continued alcohol use after diagnosis, and failure to seek timely care at onset of hematemesis.

Frequently asked questions

What is the priority nursing intervention for a patient with esophageal varices who is bleeding?

Airway protection is the first priority. A patient with massive hematemesis or altered mental status should be assessed for intubation before any other intervention, including IV access or medication administration. Aspiration of blood is a major, preventable cause of early harm in variceal hemorrhage. Once the airway is secured, the simultaneous priorities are establishing large-bore IV access, initiating octreotide infusion (50 mcg bolus, then 50 mcg/hr), and obtaining emergent endoscopy consultation.

What medications are used to treat esophageal varices?

Treatment involves two distinct phases. During acute hemorrhage, vasoactive agents – octreotide (50 mcg IV bolus, then 50 mcg/hr infusion for 2–5 days) or terlipressin (2 mg IV every 4 hours) – reduce splanchnic blood flow and portal pressure. Prophylactic antibiotics (ceftriaxone 1 g IV daily for Child-Pugh B/C) are added simultaneously. For long-term prophylaxis, non-selective beta-blockers (carvedilol 6.25–12.5 mg daily, propranolol, or nadolol) are titrated to a heart rate of 55–60 bpm.

What is the difference between primary and secondary prophylaxis for esophageal varices?

Primary prophylaxis aims to prevent the first variceal bleed using NSBBs (preferred: carvedilol per Baveno VII) or EVL for patients with medium or large varices who cannot tolerate beta-blockers. Secondary prophylaxis prevents re-bleeding after a first episode and is more aggressive: combination therapy with both EVL (every 2–4 weeks until eradication) and NSBBs together is standard, as combination therapy is superior to either intervention alone.

When is a TIPS procedure indicated for esophageal varices?

Preemptive (early) TIPS – placed within 24–72 hours of admission – is indicated for high-risk patients: Child-Pugh B with active bleeding at endoscopy, or Child-Pugh C with a score of 10–13. This approach improves 6-week and 1-year survival compared to standard EVL plus vasoactive drug therapy in this population. Rescue TIPS is used when hemorrhage is refractory to endoscopic and pharmacologic treatment. Secondary prophylaxis TIPS is reserved for patients who re-bleed despite combination EVL plus NSBB therapy.

What are the most common nursing diagnoses for esophageal varices?

The five primary NANDA-I diagnoses are: Risk for Bleeding (related to portal hypertension and coagulopathy), Decreased Cardiac Output (during active hemorrhage), Deficient Fluid Volume (from hemorrhage and third-spacing), Anxiety (from fear of recurrent life-threatening bleeding), and Deficient Knowledge (regarding NSBB adherence, EVL scheduling, warning signs, and alcohol abstinence). Risk for Bleeding is the priority diagnosis and drives the acute management protocol.

How does a nurse monitor for hepatic encephalopathy after a variceal bleed?

Post-bleed encephalopathy monitoring includes hourly neurological checks for orientation to person, place, and time; asterixis assessment (have the patient extend both arms and observe for flapping tremor – a hallmark sign); and monitoring for sleep pattern reversal (sleeping during the day, awake at night – an early sign). Lactulose is titrated to produce 2–3 soft stools daily to reduce colonic ammonia absorption. Under the 2026 ACG guideline, rifaximin 550 mg twice daily is added when encephalopathy recurs despite lactulose.

What are the nursing considerations for octreotide administration?

Administer the initial 50 mcg IV bolus slowly over 3–5 minutes to reduce nausea and flushing. The maintenance infusion runs at 50 mcg/hr via a dedicated IV line and should not be mixed with other medications. Monitor blood glucose every 4–6 hours – octreotide inhibits glucagon and insulin secretion, causing glucose fluctuations in both directions. Monitor for bradycardia and ST changes on the cardiac monitor. Document the infusion start time accurately, because vasoactive therapy is given for 2–5 days.

Why is INR an unreliable bleeding predictor in cirrhosis?

The INR measures the speed of the extrinsic coagulation pathway and reflects reduced pro-coagulant factors (II, V, VII, X, and fibrinogen) in cirrhosis – making it appear that cirrhotic patients are at high bleeding risk. What the INR does not capture is the simultaneous reduction in anticoagulant proteins (protein C, protein S, antithrombin III), which partially compensates for the pro-coagulant deficit. This rebalanced hemostasis means many cirrhotic patients have less net coagulopathy than the INR implies. Fibrinogen, platelet count, and viscoelastic tests such as thromboelastography (TEG) give additional information, but Baveno VII found no evidence that platelet count or fibrinogen predicts failure to control variceal bleeding. AASLD guidance advises against routine transfusion of plasma, platelets, or cryoprecipitate before band ligation; correction is decided case by case only when bleeding cannot be controlled.

References

1. de Franchis R; Baveno VII Faculty. Baveno VII – renewing consensus in portal hypertension. Journal of Hepatology. 2022;76(4):959-974. doi:10.1016/j.jhep.2021.12.022
2. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. New England Journal of Medicine. 2010;362(9):823-832. doi:10.1056/NEJMra0901512
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024
4. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. New England Journal of Medicine. 2013;368(1):11-21. doi:10.1056/NEJMoa1211801
5. Lo GH, Lai KH, Cheng JS, et al. A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices. Hepatology. 1995;22(2):466-471. doi:10.1002/hep.1840220215
6. Escorsell À, Bañares R, García-Pagán JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology. 2002;35(2):385-392. doi:10.1053/jhep.2002.30418
7. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. New England Journal of Medicine. 1999;341(6):403-409. doi:10.1056/NEJM199908053410603
8. Rodrigues SG, Delgado MG, Stirnimann G, Berzigotti A, Bosch J. Hepatic venous pressure gradient: measurement and pitfalls. Clinics in Liver Disease. 2024;28(3):383-400. doi:10.1016/j.cld.2024.03.009
9. Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29(6):1655-1661. doi:10.1002/hep.510290608
10. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922-938. doi:10.1002/hep.21907
11. Hernández-Gea V, Procopet B, Giráldez Á, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology. 2019;69(1):282-293. doi:10.1002/hep.30182
12. Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. Journal of Hepatology. 2000;32(1 Suppl):141-156. doi:10.1016/s0168-8278(00)80422-5
13. Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160-1170. doi:10.1053/j.gastro.2016.01.004
14. Abraldes JG, Albillos A, Bañares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136(5):1651-1658. doi:10.1053/j.gastro.2009.01.043
15. Sersté T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52(3):1017-1022. doi:10.1002/hep.23775
16. Baveno VIII Faculty. Baveno VIII – advancing consensus in portal hypertension. Journal of Hepatology. 2026;85(5):993-1018. doi:10.1016/j.jhep.2026.07.030
17. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884
18. Kaplan DE, Ripoll C, Thiele M, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79(5):1180-1211. doi:10.1097/HEP.0000000000000647
19. Northup PG, Garcia-Pagán JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):366-413. doi:10.1002/hep.31646
20. Nadim MK, Kellum JA, Forni L, Francoz C, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. Journal of Hepatology. 2024;81(1):163-183. doi:10.1016/j.jhep.2024.03.031
21. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306-333. doi:10.1002/hep.30866
22. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Critical Care Medicine. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299
23. Keung CY, Morgan A, Le ST, Robertson M, Urquhart P, Swan MP. Survival outcomes and predictors of mortality, re-bleeding and complications for acute severe variceal bleeding requiring balloon tamponade. World Journal of Hepatology. 2022;14(8):1584-1597. doi:10.4254/wjh.v14.i8.1584
24. Kim WR, Mannalithara A, Heimbach JK, Kamath PS, et al. MELD 3.0: the Model for End-Stage Liver Disease updated for the modern era. Gastroenterology. 2021;161(6):1887-1895.e4. doi:10.1053/j.gastro.2021.08.050
25. Bajaj JS, Jakab SS, Jesudian AB, Rahimi RS, Duarte-Rojo A, et al. ACG clinical guideline: hepatic encephalopathy. American Journal of Gastroenterology. 2026;121(3):588-618. doi:10.14309/ajg.0000000000003899
26. Sandostatin (octreotide acetate) injection. US prescribing information. Novartis Pharmaceuticals; DailyMed setid 4e2c9856-1836-49f0-9472-4dbeeb408f39, accessed October 17, 2026.

Related pages

• Cirrhosis nursing: pathophysiology, complications, and care
• Hepatic encephalopathy nursing reference
• Hepatorenal syndrome nursing reference
• GI bleed nursing reference: assessment and interventions
• Nursing lab values cheat sheet
• Electrolyte imbalances nursing reference